RB Capital Management LLC Has $259,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

RB Capital Management LLC reduced its position in shares of Zoetis Inc. (NYSE:ZTS) by 7.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,325 shares of the company’s stock after selling 101 shares during the quarter. RB Capital Management LLC’s holdings in Zoetis were worth $259,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of ZTS. Mizuho Securities USA LLC boosted its stake in Zoetis by 13,726.9% in the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock valued at $950,524,000 after acquiring an additional 4,829,815 shares during the last quarter. Sarasin & Partners LLP boosted its position in shares of Zoetis by 546.3% in the 2nd quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock worth $390,682,000 after purchasing an additional 1,904,899 shares during the last quarter. International Assets Investment Management LLC grew its stake in shares of Zoetis by 41,235.7% during the third quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock worth $183,652,000 after purchasing an additional 937,700 shares during the period. Marshall Wace LLP grew its stake in shares of Zoetis by 7,608.6% during the second quarter. Marshall Wace LLP now owns 835,684 shares of the company’s stock worth $144,874,000 after purchasing an additional 824,843 shares during the period. Finally, Swedbank AB increased its holdings in Zoetis by 56.2% in the second quarter. Swedbank AB now owns 1,946,277 shares of the company’s stock valued at $337,407,000 after purchasing an additional 700,398 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS stock opened at $178.12 on Tuesday. The stock has a market cap of $80.36 billion, a PE ratio of 33.48, a price-to-earnings-growth ratio of 2.88 and a beta of 0.89. The stock has a 50-day moving average price of $181.72 and a two-hundred day moving average price of $181.12. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same period last year, the company earned $1.36 earnings per share. Zoetis’s quarterly revenue was up 11.6% on a year-over-year basis. Equities analysts forecast that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st were given a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a yield of 0.97%. The ex-dividend date was Thursday, October 31st. Zoetis’s dividend payout ratio (DPR) is currently 32.52%.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. UBS Group initiated coverage on Zoetis in a report on Monday. They set a “neutral” rating and a $196.00 target price on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. BTIG Research upped their target price on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Stifel Nicolaus boosted their price target on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $216.70.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.